Ami Organics bolsters collaboration with Fermion, signs agreement for new pharma intermediates

Ami Organics Limited, a global leader in manufacturing advanced pharmaceutical intermediates and specialty chemicals, has signed a definitive agreement with Fermion, a subsidiary of Orion Corporation, Finland. This agreement marks the addition of two more advanced pharmaceutical intermediates to the company’s manufacturing portfolio for Fermion.

The intermediates, to be produced under this agreement, will be used in the captive consumption for earlier intermediates agreed upon with Fermion. This development will add value to the final advanced intermediates supplied by Ami Organics to Fermion, enhancing the overall value of the end product. This move positions Ami Organics as a leading supplier of key advanced intermediates for Fermion.

The products under the new agreement are slated for manufacturing at Ami Organics’ Ankleshwar Facility and are expected to contribute significantly to the company’s revenue from FY25. Ami Organics has previously signed two agreements with Fermion in November 2022 and September 2023 for the supply of two advanced pharmaceutical intermediates. The latest agreement further strengthens and increases the total value of the CDMO (Contract Development and Manufacturing Organization) contract with Fermion.

Ami Organics to Manufacture Advanced Intermediates for Fermion, Strengthening Global Presence

Naresh Patel, Executive Chairman & Managing Director of Ami Organics Limited, commented on this development, stating, “We are delighted to enhance our relationship with our esteemed customer, Fermion, by signing agreements for two more advanced pharmaceutical intermediates. This new agreement underscores our commitment to delivering value-added products and the confidence Fermion has in our capabilities.”

Headquartered in Surat, Ami Organics is a research and development-driven manufacturer specializing in specialty chemicals with a focus on developing and manufacturing advanced pharmaceutical intermediates for regulated markets, generic APIs, New Chemical Entities (NCE), and key starting materials for agrochemical and fine chemicals. Since its inception, Ami Organics has developed and commercialized over 520+ Pharma Intermediates for APIs across 23 key therapeutic areas and NCE, emphasizing R&D in select high-growth, high-margin chronic therapeutic areas.

This expanded partnership with Fermion represents a significant step forward for Ami Organics in the global pharmaceutical market. It showcases the company’s dedication to innovation and its ability to meet the evolving needs of the healthcare sector, further solidifying its position as a key player in the international chemical industry.